Related Experiment Video
Updated: Jul 5, 2025

10:36
Rare Event Detection Using Error-corrected DNA and RNA Sequencing
Published on: August 3, 2018
12.1K
Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error
Medrxiv : the Preprint Server for Health Sciences
|January 23, 2024
Summary
AccuScan technology significantly reduces whole genome sequencing errors for cell-free DNA analysis. This breakthrough enables highly sensitive detection of molecular residual disease (MRD) and predicts relapse across multiple cancer types.
Area of Science:
- Genomics
- Molecular Biology
- Cancer Research
Background:
- Whole genome sequencing (WGS) of cell-free DNA (cfDNA) is promising for molecular residual disease (MRD) detection.
- High error rates in WGS currently limit its sensitivity for MRD detection.
Conclusions:
- AccuScan provides a highly accurate WGS solution for MRD detection.
- Enables sensitive circulating tumor DNA detection at parts per million levels without high sample input or personalized reagents.
- AccuScan offers a low-input, reagent-free method for early cancer detection and monitoring.

